Investors

Investors image

News

Sep.03, 2025 Release
FDA Accepts Shionogi’s Ensitrelvir NDA for Review as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Sep.01, 2025 Release
Notice of Acquisition of TORII PHARMACEUTICAL CO., LTD. as a Wholly-Owned Subsidiary
Aug.29, 2025 Release
Shionogi & Co., Ltd. Selected for METI’s FY2024 Supplementary Budget Grant Program for Future-Oriented Co-Creation with the Global South – Feasibility Study on the Use of Digital Solutions to Promote Appropriate Use of Japan-Origin Antimicrobials and Hygiene Products in Kenyan Healthcare Facilities –
Aug.04, 2025 Notice
Shionogi to Exhibit at the 9th Tokyo International Conference on African Development (TICAD9) and Participate in a Stage Event
Jul.30, 2025 Notice
Notice Transcript of FY2025 1Q Results Meeting
  • Latest IR Information

    ・Financial Results / Supplement

    　- Presentation material

    　- Transcript

    more
  • IR Library

    ・Financial Results / Supplement

    ・Presentation materials

    ・Annual Report / Integrated Report / EHS Report

    ・Corporate Governance Report

    ・Pipeline

    ・Fact Book

    more
  • Management Policy

    ・Philosophy

    ・Business Plan

    ・Corporate Governance

    ・Disclosure Policy

    ・Business Risks

    more
  • Shareholder Information

    ・Information on Shares

    ・General Meeting of Shareholders

    ・Analyst Coverage

    ・Bonds & Ratings

    more
  • Individual Investors

    ・Pharmaceutical Business

    ・Shionogi's Strength

    ・Business Strategy

    ・Business Activities, etc.

     

    more
  • Sustainability

    View the Shionogi's approach to sustainable growth

    more
  • Financial Highlights

    Financial highlights for the last five years

    more
  • IR Calendar

    The schedule and results of IR events in each fiscal year

     

    more